Gender Clinic Whistleblower Thought She Was Helping Kids but She Was Wrong | Jamie Reed (#49)
20 November 2025
With Jamie Reed
North America
Jamie Reed worked as a case manager at a paediatric gender centre in St. Louis for four years before filing a 23-page affidavit with Missouri's Attorney General. Her account, along with subsequent legal and regulatory proceedings, contributed to the clinic halting treatment of minors. Her trajectory from convinced insider to public whistleblower mirrors questions now being asked formally across Europe: whether clinical practice in paediatric gender medicine outran the evidence, and how institutional culture made that possible.
Jamie Reed joined Washington University's paediatric gender centre in 2018 with a background that made her a credible hire. A lesbian who had spent more than a decade in HIV medicine, she had practical experience helping patients navigate name changes, gender marker updates, and accommodation letters. She had read the WPATH Standards of Care before taking the position and, by her own account, entered the role as a genuine believer in its clinical framework. She describes herself as politically to the left of the mainstream. Four years later she left, and began preparing a legal document. In early 2023, Reed filed a 23-page affidavit with Missouri's Attorney General and published an article describing what she had witnessed during her time at the centre. The article circulated widely. Her account drew sustained scrutiny to the clinical practices of a programme that was, at the time of her departure, one of the larger paediatric gender centres in the United States. Nineteen months after the article appeared, the clinic ceased providing gender-related medical treatment to minors. The affidavit is a public document and has been cited in legal and legislative proceedings since. This episode traces her journey from committed advocate to whistleblower: how her initial confidence in the clinical model gave way to concern, why she concluded that internal channels were insufficient, and what it cost her to go public. She also addresses the personal dimension of her situation. Her partner at the time she was employed was identifying as male; that partner detransitioned approximately two years after Reed went public in February 2023. Reed's account reaches audiences at a moment when paediatric gender medicine has come under formal institutional scrutiny across multiple jurisdictions. The Cass Review, commissioned by NHS England and published in 2024, concluded after a four-year systematic evidence review that the research base supporting puberty blockers and cross-sex hormones in adolescents was of poor quality and that clinical practice had moved ahead of the evidence. Sweden, Finland, Norway, and Denmark have each implemented restrictions or significant reforms to their paediatric gender programmes, citing comparable evidentiary concerns. In each case, the institutional pivot followed a period in which clinical confidence had outrun the underlying research. What Reed's testimony adds to that documentary record is a detailed account of how that confidence operates from the inside. Systematic reviews assembled by national health bodies address clinical outcomes. Reed addresses clinical process: the institutional pressures, the daily decisions, the distance between professional consensus and individual clinical hesitation. The question her episode raises — whether and how clinical culture suppresses the kind of uncertainty that ought to drive evidence-gathering — is central to formal inquiries now under way in Europe and to ongoing litigation in the United States. Her decision to speak, and the chain of consequences that followed, are themselves part of the evidence trail.
